Please provide your email address to receive an email when new articles are posted on . Dual antiplatelet therapy for 1 month or 3 months was noninferior to a 12-month duration with regard to ...

Trials and subanalyses of shorter dual antiplatelet therapy (DAPT) duration following PCI continue to trickle in from the major cardiology meetings—today’s from TCT 2021—amid growing consensus that ...

(UPDATED) MASTER DAPT, the latest and largest randomized clinical trial to tackle the conundrum of dual antiplatelet therapy (DAPT) duration in post-PCI patients at high risk for bleeding, indicates ...

Please provide your email address to receive an email when new articles are posted on . Among patients who underwent PCI with a sirolimus-eluting stent, short-term and long-term dual antiplatelet ...

For high-bleeding risk patients, a shorter duration of dual antiplatelet therapy (DAPT) appeared just as safe for those getting novel stent after acute myocardial infarction (MI) in the MASTER-DAPT ...

DUBLIN, June 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for a one-month dual ...

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not increase myocardial infarction (MI) or stent thrombosis (ST) in high bleeding risk (HBR) ...

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having excessive bleeding in the months following the procedure. While routine ...